SHERP

Fibrinolysis in vivo Predicts a Favorable Outcome in Patients with Small Vessel Thrombi: Observations in Patients with Glomerular Thrombi during Treatment with Ancrod
신사구체소혈관내 혈전증에서 섬유소용해의 효과

Cited 0 time in webofscience Cited 0 time in scopus
Authors
Kim, Suhnggwon; Han, Jin Suk; Lee, Jung Sang
Issue Date
1988-06
Publisher
Seoul National University College of Medicine
Citation
Seoul J Med 1988;29(2):155-165
Keywords
FibrinolysisGlomerulonephritsGlomerular thrombiFibrinolytic drug
Abstract
Fibrin deposits injure small vessels. To evaluate the effect of fibrinolysis, patients
with glomerular diseases having glomerular thrombi received the snake venom enzyme,
ancrod, for 14 days. Within 48 hours, the mean level of fibrin/fibrinogen degradation products(
FOP) was very high, and bimodally distributed, defining lowln = 11) and high(n = 18)
FOP responses.
In the low FOP group, the FOP rise and fibrinogen decrease were linearly related, suggesting
that most FOP derived from fibrinogen degradation. Renal effects were minimal. In the
high FOP group, the FOP level was not explained by fibrinogen degradation alone, indicating
fibrin dissolution. Renal function improved, proteinuria increased, and glomerular fibrin deposition
decreased.
Tissue type plasminogen activator, released by ancrod-frbim from endothelial cells, converts
fibrin-bound plasminogen to palsmin, which degrades fibim. Alpha--antiplasrnin, the most
effective known inhibitor of fibrinolysis, was elevated in 9/11 in the low, and 5/18 in the high
FOP group. Thus when fibrinolysis occurred, it was associated with rapid favorable effects on
renal function and histology.
ISSN
0583-6802
Language
English
URI
http://hdl.handle.net/10371/6376
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)The Seoul Journal of MedicineThe Seoul Journal of Medicine Vol. 29 No.2 (1988)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse